184 related articles for article (PubMed ID: 19320777)
21. Activating Gs(alpha) mutation in intramuscular myxomas with and without fibrous dysplasia of bone.
Okamoto S; Hisaoka M; Ushijima M; Nakahara S; Toyoshima S; Hashimoto H
Virchows Arch; 2000 Aug; 437(2):133-7. PubMed ID: 10993273
[TBL] [Abstract][Full Text] [Related]
22. Mutation profile of high-grade appendiceal mucinous neoplasm.
Liao X; Vavinskaya V; Sun K; Hao Y; Li X; Valasek M; Xu R; Polydorides AD; Houldsworth J; Harpaz N
Histopathology; 2020 Feb; 76(3):461-469. PubMed ID: 31491041
[TBL] [Abstract][Full Text] [Related]
23. GNAS and KRAS Mutations Define Separate Progression Pathways in Intraductal Papillary Mucinous Neoplasm-Associated Carcinoma.
Tan MC; Basturk O; Brannon AR; Bhanot U; Scott SN; Bouvier N; LaFemina J; Jarnagin WR; Berger MF; Klimstra D; Allen PJ
J Am Coll Surg; 2015 May; 220(5):845-854.e1. PubMed ID: 25840541
[TBL] [Abstract][Full Text] [Related]
24. Local recurrence of myxofibrosarcoma is associated with increase in tumour grade and cytogenetic aberrations, suggesting a multistep tumour progression model.
Willems SM; Debiec-Rychter M; Szuhai K; Hogendoorn PC; Sciot R
Mod Pathol; 2006 Mar; 19(3):407-16. PubMed ID: 16415793
[TBL] [Abstract][Full Text] [Related]
25. Lobular endocervical glandular hyperplasia is a neoplastic entity with frequent activating GNAS mutations.
Matsubara A; Sekine S; Ogawa R; Yoshida M; Kasamatsu T; Tsuda H; Kanai Y
Am J Surg Pathol; 2014 Mar; 38(3):370-6. PubMed ID: 24145653
[TBL] [Abstract][Full Text] [Related]
26. Frequent GNAS and KRAS mutations in pyloric gland adenoma of the stomach and duodenum.
Matsubara A; Sekine S; Kushima R; Ogawa R; Taniguchi H; Tsuda H; Kanai Y
J Pathol; 2013 Mar; 229(4):579-87. PubMed ID: 23208952
[TBL] [Abstract][Full Text] [Related]
27. Mutational analysis of high-grade spindle cell sarcoma of the femur in Mazabraud's syndrome.
Calleja M; Amary F; O'Donnell P
Skeletal Radiol; 2019 Jan; 48(1):151-157. PubMed ID: 29804209
[TBL] [Abstract][Full Text] [Related]
28. GNAS Is frequently mutated in a specific subgroup of intraductal papillary neoplasms of the bile duct.
Tsai JH; Yuan RH; Chen YL; Liau JY; Jeng YM
Am J Surg Pathol; 2013 Dec; 37(12):1862-70. PubMed ID: 24061513
[TBL] [Abstract][Full Text] [Related]
29. Presence of activating KRAS mutations correlates significantly with expression of tumour suppressor genes DCN and TPM1 in colorectal cancer.
Mlakar V; Berginc G; Volavsek M; Stor Z; Rems M; Glavac D
BMC Cancer; 2009 Aug; 9():282. PubMed ID: 19678923
[TBL] [Abstract][Full Text] [Related]
30. Mutation of TP53 and alteration of p14(arf) expression in EGFR- and KRAS-mutated lung adenocarcinomas.
Cortot AB; Younes M; Martel-Planche G; Guibert B; Isaac S; Souquet PJ; Commo F; Girard P; Fouret P; Brambilla E; Hainaut P; Soria JC
Clin Lung Cancer; 2014 Mar; 15(2):124-30. PubMed ID: 24169260
[TBL] [Abstract][Full Text] [Related]
31. Analysis of GNAS1 and PRKAR1A gene mutations in human cardiac myxomas not associated with multiple endocrine disorders.
Mantovani G; Bondioni S; Corbetta S; Menicanti L; Rubino B; Peverelli E; Labarile P; Dall'Asta C; Ambrosi B; Beck-Peccoz P; Lania AG; Spada A
J Endocrinol Invest; 2009 Jun; 32(6):501-4. PubMed ID: 19494712
[TBL] [Abstract][Full Text] [Related]
32. The discrete nature and distinguishing molecular features of pancreatic intraductal tubulopapillary neoplasms and intraductal papillary mucinous neoplasms of the gastric type, pyloric gland variant.
Yamaguchi H; Kuboki Y; Hatori T; Yamamoto M; Shimizu K; Shiratori K; Shibata N; Shimizu M; Furukawa T
J Pathol; 2013 Nov; 231(3):335-41. PubMed ID: 23893889
[TBL] [Abstract][Full Text] [Related]
33. EUS-guided pancreatic fluid aspiration for DNA analysis of KRAS and GNAS mutations for the evaluation of pancreatic cystic neoplasia: a pilot study.
Siddiqui AA; Kowalski TE; Kedika R; Roy A; Loren DE; Ellsworth E; Adler D; Finkelstein SD
Gastrointest Endosc; 2013 Apr; 77(4):669-70. PubMed ID: 23498145
[No Abstract] [Full Text] [Related]
34. The association between tumour progression and vascularity in myxofibrosarcoma and myxoid/round cell liposarcoma.
Mentzel T; Brown LF; Dvorak HF; Kuhnen C; Stiller KJ; Katenkamp D; Fletcher CD
Virchows Arch; 2001 Jan; 438(1):13-22. PubMed ID: 11213831
[TBL] [Abstract][Full Text] [Related]
35. Morphologic and molecular characterization of traditional serrated adenomas of the distal colon and rectum.
Wiland HO; Shadrach B; Allende D; Carver P; Goldblum JR; Liu X; Patil DT; Rybicki LA; Pai RK
Am J Surg Pathol; 2014 Sep; 38(9):1290-7. PubMed ID: 25127095
[TBL] [Abstract][Full Text] [Related]
36. Fine-needle aspiration of soft tissue perineurioma: A comparative analysis of cytomorphology and immunohistochemistry with benign and malignant mimics.
Yang EJ; Hornick JL; Qian X
Cancer Cytopathol; 2016 Sep; 124(9):651-8. PubMed ID: 27159449
[TBL] [Abstract][Full Text] [Related]
37. KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma.
Sinn BV; Striefler JK; Rudl MA; Lehmann A; Bahra M; Denkert C; Sinn M; Stieler J; Klauschen F; Budczies J; Weichert W; Stenzinger A; Kamphues C; Dietel M; Riess H
Pancreas; 2014 May; 43(4):578-83. PubMed ID: 24681874
[TBL] [Abstract][Full Text] [Related]
38. Frequent activating GNAS mutations in villous adenoma of the colorectum.
Yamada M; Sekine S; Ogawa R; Taniguchi H; Kushima R; Tsuda H; Kanai Y
J Pathol; 2012 Sep; 228(1):113-8. PubMed ID: 22374786
[TBL] [Abstract][Full Text] [Related]
39. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
[TBL] [Abstract][Full Text] [Related]
40. Genetic analysis in APC, KRAS, and TP53 in patients with stomach and colon cancer.
Palacio-Rúa KA; Isaza-Jiménez LF; Ahumada-Rodríguez E; Muñetón-Peña CM
Rev Gastroenterol Mex; 2014; 79(2):79-89. PubMed ID: 24861525
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
